Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

11 juillet 2018

15:13
Scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine today announced the launch of a new clinical trial that will assess the impact of high-dose omega-3 fatty acids and vitamin D supplementation...

12:49
Airweave Inc. is pleased to announce that a sleep study funded by Airweave, inc, and led by Seiji Nishino, MD, PhD., emeritus professor of psychiatry and behavioral sciences and director of the Sleep and Circadian Neurobiology Laboratory at the...

12:45
- Phase 1 data from the study expected to be available by December 2018 Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders, announced today that it has commenced dosing in INDUS, a...

08:33
BioSight Ltd., a pharmaceutical development company focused on the development of targeted oncology drugs, announced today that it has received the FDA and the Israeli Ministry of Health clearance to launch a Phase 2b clinical trial of BST-236 for...

08:15
MarketNewsUpdates.com News Commentary  Clinical trial development is advancing ways to support sponsors and partnerships as biotech and pharmaceutical companies race to find, develop and deliver immuno-oncology (IO) therapies to the growing number...

08:07
Gyncentrum Clinic has just announced the world's first pregnancies using a more natural fertilisation method with donor eggs. "We are very happy about GynCentrum's having the first pregnancies with Egg donation in the world. Gyncentrum is again...

08:00
- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. Fourteen Phase 3 company-sponsored studies are ongoing. - The...

08:00
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today topline results from the Phase 3 PHOENIX trial evaluating the investigational use of IMBRUVICA® (ibrutinib) in the treatment of newly diagnosed non-Germinal Center B cell...

07:15
L'étude est conçue pour évaluer l'efficacité des capsules d'huile de cannabidiol de CannTrust dans le ralentissement de la progression de la sclérose latérale amyotrophique (SLA).  CannTrust Holdings Inc. (« CannTrust » ou la « Société ») , un des...

07:15
CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST), one of Canada's leading licensed producers of medical cannabis, announced today that it has partnered with Australia's Gold Coast University Hospital ("Gold Coast") to conduct a...

05:30
Achieve Life Sciences, Inc. , a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting...

03:17
Cantargia AB announce that the European Patent Office (EPO) has issued an Intention to grant notification for the company's divisional (second, follow-up) patent application regarding use of IL1RAP as a target for antibody therapy in solid tumours....

03:07
Gyncentrum Clinic has just announced the world's first pregnancies using a more natural fertilisation method with donor eggs. "We are very happy about GynCentrum's having the first pregnancies with Egg donation in the world. Gyncentrum is again...

02:07
La clinique Gyncentrum vient d'annoncer les premières grossesses au monde employant une méthode de fécondation plus naturelle par don d'ovules.  « Nous sommes ravis d'annoncer les premières grossesses au monde utilisant la méthode Egg Donation à la...


10 juillet 2018

16:07
Ceribell, Inc. announced that its Rapid Response EEG System provides significant improvement in setup time compared with conventional electroencephalography (EEG) and resulted in a significant net reduction in unnecessary treatments with...

16:05
Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program Results confirm strong clinical activity of oral SCY-078 and suggest improved sustained benefit relative to the...

15:05
For patients with early kidney cancer, removing part of the kidney instead of the whole kidney is often a preferred treatment because the procedure can effectively remove tumors while preserving kidney function. But when it comes to the best surgical...

13:44
Baxter Canada today announced Health Canada's approval of a new indication for the company's oXiris set, which can now...

13:05
OxThera AB, société pharmaceutique privée basée à Stockholm, a annoncé aujourd'hui que l'étude multicentrique de Phase III visant à évaluer Oxabact® dans l'hyperoxalturie primaire (HP) est maintenant entièrement ouverte au recrutement. L'étude est...

13:01
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria (PH) is now fully open for recruitment. All clinics participating in the study are approved...

10:15
A recent clinical study lead by the Ablon Institute of Research shows that Nutrafol®, the natural nutraceutical for healthy hair, effectively helps promote healthy hair growth and improves overall hair quality in women. The successful results were...

09:37
Digital therapeutics company, Revon Systems will be working with AstraZeneca's Innovative Medicine and Early Development (IMED) Biotech Unit in respiratory clinical trials to evaluate CompEx, a novel therapeutic endpoint for asthma. CompEx is an...

09:03
MMS Holdings Inc. (MMS) ? a global, leading clinical research organization ? announced today its integrated support for Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...

08:30
VolitionRx Limited  ("Volition") today announced that it has added to its already impressive clinical trial program with the execution of additional agreements to conduct large-scale colorectal cancer research studies across the Asia Pacific...

08:30
U.S. Stem Cell, Inc. , a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has demonstrated successful, in-human results in repairing meniscus tear after...

07:00
ArmaGen, Inc., a privately held biotechnology company focused on developing groundbreaking therapies to treat severe neurological disorders, today released the full results from a 52-week Phase 1/2 proof-of-concept study of AGT-181 (valanafusp alpha)...

07:00
Myovant Sciences , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that it has completed screening patients for its LIBERTY 1 study,...

07:00
Recursion, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover drugs at scale, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug...

06:47
BioArctic AB (publ) announced today that the company has received approval by Fimea, the Finnish Medicines Agency, and Valvira, the Finnish authority for medical device, as well as the local ethics committee for inclusion of Finnish patients in...

05:00
PITTSBURGH, July 10, 2018 /PRNewswire-PRWeb/ -- Circadiance, a pioneer in remote patient monitoring specializing in the infant apnea arena, exhibited and presented at the VGM Heartland Conference during the week of June 19, 2018. Circadiance...

03:01
Otsuka Holdings Co., Ltd. ("Otsuka Holdings"), Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") and ReCor Medical, Inc. ("ReCor") announce the signing of a merger agreement pursuant to which Otsuka Holdings will acquire the remaining...

00:30
CS Genetics, a developer of tools and techniques for genomics, has made a sequence of scientific, conceptual, and analytic advances regarding circulating nucleic acids which yield a powerful new modality for the noninvasive diagnosis of cancer and...


9 juillet 2018

22:45
BioArctic AB (publ) announces today the results of the BAN2401 Phase 2b clinical study (ClinicalTrials.gov identifier NCT01767311), will be presented in an oral session at the 2018 Alzheimer's Association International Conference (AAIC) on July 25,...

22:20
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be presented in an oral session at the 2018 Alzheimer's...

20:08
Adagene, Inc., an innovative antibody engineering and discovery company, has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors...

19:00
OBI Pharma, Inc., une société biopharmaceutique taïwanaise (TPEx : 4174), a annoncé aujourd'hui que l'Agence américaine des produits alimentaires et médicamenteux (FDA) des États-Unis a accordé la désignation de médicament orphelin à OBI-3424 pour le...

14:27
Specializing in Alzheimer's Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials (NCT)...

13:30
JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed rituximab biosimilar,...

08:00
Researchers at Hospital for Special Surgery in New York City are launching a new study to identify inflammatory molecules that might help improve treatment of people with certain knee injuries. The goals of the study,...

08:00
Citius Pharmaceuticals, Inc. ("Citius") ("Company") , a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report on the progress of the Mino-Lok Phase 3 clinical program. The...

08:00
Trovagene, Inc. , a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today provided an update on key value-creating milestones for the second half of 2018 and a...

08:00
Seattle Genetics, Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced completion of enrollment for the enfortumab vedotin EV-201 pivotal phase 2 clinical trial cohort of patients with...

08:00
PTC Therapeutics, Inc. today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that the safety and pharmacokinetic profile of Translarna in children from two to five years with nonsense mutation...

07:30
BELLUS Santé inc. (« BELLUS Santé » ou la « société »), une société biopharmaceutique de développement de nouveaux médicaments ciblant des maladies pour lesquelles il existe d'importants besoins médicaux non comblés, a annoncé aujourd'hui le début...

07:30
BELLUS Health Inc. ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced the initiation of healthy subjects dosing in a Phase 1 clinical...

07:30
Aeromics, Inc. ("Aeromics" or "the Company"), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic stroke, announced today the initiation...

07:03
At the Intelligent Medicines' Future Decoded event co-hosted by Microsoft, Indegene and PAREXEL, life sciences leaders reunited at the Microsoft Research Lab in Cambridge and showcased digital advances in their industry. CIOs, CMOs, Digital Strategy,...

07:00
CTI BioPharma Corp. and Servier today announced that the pivotal Phase III trial (PIX306) evaluating PIXUVRI® (pixantrone) combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin...

07:00
Cellect Biotechnology Ltd. , a developer of a novel stem cell production technology, announced that it has entered into a strategic manufacturing and supply agreement with Swiss Biotech Center (SBC) to secure production of FasL protein - Cellect's...

06:58
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Immune Pharmaceuticals ("Immune"), a biopharmaceutical company...